Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk protein, Dickkopf-2 (Dkk-2), acts to stimulate bone formation independently of Wnt proteins which may be inhibited and/or antagonized by Dkk-2. Dkk-2 displayed enhanced specific targeting ability and enhanced biological activity in stimulating or enhancing mineralization. Dkk-2 also played a role in the differentiation and self-renewal of hematopoietic stem cells and mesenchymal stem cells, particularly in osteoblastogenesis and osteoclastogenesis.
1. A method for stimulating or enhancing bone formation in a mammalian subject in need thereof, comprising administering to the mammalian subject at least one Dkk2 protein, a fragment of a Dkk2 protein capable of stimulating or enhancing bone formation, or a combination thereof.
2. A method for stimulating or enhancing osteoblast mineralization in a mammalian subject in need thereof, comprising administering to the mammalian subject at least one Dkk2 protein, a fragment of a Dkk2 protein capable of stimulating or enhancing osteoblast mineralization, or a combination thereof.
3. A method for regulating the proliferation of osteoblast progenitor cells in a mammalian subject in need thereof, comprising administering to the mammalian subject at least one Dkk2 protein, a fragment of a Dkk2 protein capable of regulating the proliferation of osteoblast progenitor cells, or a combination thereof.
4. A method for directly accelerating the differentiation of osteoblasts in a mammalian subject in need thereof, comprising administering to the mammalian subject at least one Dkk2 protein, a fragment of a Dkk2 protein capable of directly accelerating the differentiation of osteoblasts, or a combination thereof.
5. The method of any one of claims 1 , 2 , 3 or 4 , wherein administering comprises inhalation, oral, intravenous, intraperitoneal, intramuscular, parenteral, transdermal, intravaginal, intranasal mucosal, sublingual, topical, rectal or subcutaneous administration, or any combination thereof.
6. The method of any one of claim 1 , 2 , 3 or 4 , comprising administering the at least one Dkk2 protein.
7. The method of any one of claim 1 , 2 , 3 or 4 , wherein said Dkk2 protein is administered to a bone.
8. The method of claim 7 , wherein said bone has a disease, fracture, injury or abnormality.
9. The method of any one of any one of claim 1 , 2 , 3 or 4 , wherein said Dkk2 protein or fragment is administered as a vector expressing a Dkk2 protein.
10. The method of claim 9 , wherein said vector is a viral vector.
11. The method of claim 10 , wherein said viral vector is a retrovirus, an adenovirus, or an adeno-associated virus.
12. The method of claim 9 , wherein said vector is administered to a cell in vitro and the cell is transplanted into the mammalian subject.
13. The method of claim 12 , wherein said cell is a hematopoietic stem cell, a mesenchymal stem cell, or a bone marrow stromal cell.
14. The method of claim 12 , wherein said cell is from said mammalian subject.
15. The method of claim 12 , wherein said cell is grown in the presence of a feeder layer prior to transplantation.